Lavender Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-11-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 26.07 Cr
as on 15-11-2024
- Revenue 6.18%
(FY 2023)
- Profit -2.63%
(FY 2023)
- Ebitda -4.90%
(FY 2023)
- Net Worth 27.42%
(FY 2023)
- Total Assets -8.21%
(FY 2023)
About Lavender Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹26.07 Cr.
Satish Mache, Atul Doke, Dnyandeo Pathare, and One other member serve as directors at the Company.
- CIN/LLPIN
U24114PN2009PTC134215
- Company No.
134215
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Lavender Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandrao Thombare  | Director | 30-Jun-2009 | Current |
| Satish Mache | Director | 30-Jun-2009 | Current |
| Atul Doke | Director | 30-Jun-2009 | Current |
| Dnyandeo Pathare | Director | 30-Jun-2009 | Current |
Financial Performance of Lavender Laboratories.
Lavender Laboratories Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.18% increase. The company also saw a slight decrease in profitability, with a 2.63% decrease in profit. The company's net worth Soared by an impressive increase of 27.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lavender Laboratories?
In 2023, Lavender Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lavender Synthopharma Private LimitedActive 3 years 4 monthsSatish Mache, Atul Doke and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 29 Jul 2024 | ₹6.00 Cr | Open |
Canara Bank Creation Date: 06 May 2024 | ₹2.50 Cr | Open |
Canara Bank Creation Date: 10 May 2023 | ₹2.78 M | Open |
How Many Employees Work at Lavender Laboratories?
Lavender Laboratories has a workforce of 102 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lavender Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lavender Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
